ProPhase Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate
ProPhase Labs, Inc. (PRPH) reported Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate of 4.20% for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-01.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate · last filed 2025-04-01
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2024-03-31 was 4.20%, a 10.53% increase year-over-year.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for the quarter ending 2023-03-31 was 3.80%.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2024 was 4.20%, a 13.51% increase from fiscal 2023.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2023 was 3.70%, a 48.00% increase from fiscal 2022.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2022 was 2.50%, a 212.50% increase from fiscal 2021.
- ProPhase Labs, Inc. share-based compensation arrangement by share-based payment award, fair value assumptions, risk free interest rate for fiscal 2021 was 0.80%.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate 12 month as first filed |
|---|---|---|---|---|---|
| 2024-12-31 | 4.20% 10-K · filed 2025-04-01 | ||||
| 2024-09-30 | 4.20% 10-Q · filed 2024-11-13 | ||||
| 2024-06-30 | 4.20% 10-Q · filed 2024-08-14 | ||||
| 2024-03-31 | 4.20% 10-Q · filed 2024-05-10 | ||||
| 2023-12-31 | 3.70% 10-K · filed 2025-04-01 | ||||
| 2023-09-30 | 3.70% 10-Q · filed 2024-11-13 | ||||
| 2023-06-30 | 3.70% 10-Q · filed 2024-08-14 | ||||
| 2023-03-31 | 3.80% 10-Q · filed 2024-05-10 | ||||
| 2022-12-31 | 2.50% 10-K · filed 2024-03-29 | 250.00% 10-K · filed 2023-03-29 | |||
| 2022-09-30 | 2.30% 10-Q · filed 2022-11-10 | ||||
| 2022-06-30 | 3.00% 10-Q · filed 2022-08-12 | ||||
| 2021-12-31 | 0.80% 10-K · filed 2023-03-29 | 80.00% 10-K · filed 2022-03-31 | |||
| 2021-09-30 | 0.70% 10-Q · filed 2022-11-10 | ||||
| 2021-06-30 | 0.60% 10-Q · filed 2022-08-12 | ||||
| 2020-12-31 | 0.00% 10-K · filed 2022-03-31 | ||||
| 2019-12-31 | 2.00% 10-K · filed 2021-03-31 | ||||
| 2018-12-31 | 2.00% 10-K · filed 2020-03-26 | ||||
| 2017-12-31 | 2.00% 10-K · filed 2019-03-26 | ||||
| 2017-09-30 | 1.62% 10-Q/A · filed 2018-08-20 | ||||
| 2017-06-30 | 1.81% 10-Q/A · filed 2018-08-20 | ||||
| 2015-12-31 | 0.88% 10-K/A · filed 2018-08-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |